Unity Biotechnology, Inc.
UNBX
Other OTC0.06
USD
- -
- -
CIK
0001463361
ISIN
US91381U2006
CUSIP
91381U200
Return %
Stock
S&P500
1Y
-95.72
19.01
3Y
-97.87
65.48
5Y
-99.88
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Craig R. Jalbert
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 285 East Grand Ave. San Francisco CA United States of America 94080
- IPO Date
- May 3, 2018
- CIK
- 0001463361
- Website
- unitybiotechnology.com
- Similar Companies
- Business
- Unity Biotechnology, Inc. develops therapeutics aimed at extending human healthspan by targeting cellular senescence, focusing initially on diseases associated with senescent cell accumulation. The company’s main products include UBX1325, a potent small molecule BCL-xL inhibitor designed to eliminate senescent cells in retinal diseases, primarily for diabetic macular edema (DME) and age-related macular degeneration (AMD). Additional pipeline candidates feature UBX2050, a fully human Tie2-activating monoclonal antibody, and UBB2048, a bispecific antibody that activates Tie2 and neutralizes VEGF, both aimed at restoring healthy vasculature and inhibiting pathological neovascularization in ocular conditions. Unity operates within biopharmaceutical segments targeting age-related and chronic diseases and conducts clinical development primarily in the US. Recent major changes include the company's strategic operational restructuring to conserve capital, which involved a workforce reduction and management transitioning to consulting roles, reflecting a shift toward exploring strategic alternatives such as asset sales, partnerships, or potential company dissolution. The company reported complete 36-week Phase 2b ASPIRE study results for UBX1325 in DME patients, indicating vision improvements comparable and statistically non-inferior to aflibercept in difficult-to-treat populations. Unity also transitioned its stock listing from Nasdaq to OTC Markets in mid-2025. Strategic partnerships with firms like Vestrum Health and CorEvitas have been integral to advancing clinical trial efficiency and patient enrollment. Additionally, notable shareholder changes include a significant equity acquisition by Alyeska Investment Group L.P., underscoring investor interest in Unity’s innovative therapies. Founded in 2011 and headquartered in San Francisco, California, Unity Biotechnology targets the biotechnology industry’s intersection of regenerative medicine and senolytic drug development. Its products and pipeline address retinal diseases and other age-related conditions with high unmet medical need. The company’s development strategy involves creating first-in-class senolytic therapies and leveraging strategic collaborations for clinical trial execution and potential commercialization. Unity’s scientific platform emphasizes selective removal of senescent cells to restore tissue function and mitigate chronic inflammation. The company operates primarily in North America with research collaborations targeting international drug development and commercialization. Unity Biotechnology’s portfolio and operations reflect its commitment to pioneering novel therapies addressing aging-related diseases, with a specific focus on retinal disorders. Despite operational challenges and strategic evaluation of future directions, the company continues advancing its lead candidate through late-stage clinical trials and maintaining collaborations crucial for clinical development success. Its recent financial and clinical updates highlight a pivotal phase in its pipeline progression and corporate strategy as it navigates the competitive and evolving biotechnology landscape. Unity Biotechnology is publicly traded under the ticker UBX on OTC Markets following its Nasdaq delisting in July 2025. The company remains engaged in exploring multiple pathways for its pipeline advancements and operational sustainability amid ongoing clinical trial data readouts and market developments.